10/527,398D Yong Chu 12/13/2006

$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS 25	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 26	DEC 11	CAS REGISTRY chemical nomenclature enhanced

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8
 NEWS X25       X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:04:14 ON 13 DEC 2006

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:04:28 ON 13 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 DEC 2006  HIGHEST RN 915277-53-1
DICTIONARY FILE UPDATES:  12 DEC 2006  HIGHEST RN 915277-53-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10527398\10527398D.str
```





chain nodes :
6 7 8 15 16
ring nodes :
1 2 3 4 5 9 10 11 12 13
chain bonds :
2-7 5-6 6-8 7-15 7-16 8-9
ring bonds :
1-2 1-5 2-3 3-4 4-5 9-10 9-13 10-11 11-12 12-13
exact/norm bonds :
1-2 1-5 2-3 2-7 3-4 4-5 5-6 6-8 7-15 7-16 8-9 9-10 9-13 10-11 11-12
12-13

G3:H,CH

G4:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1
G2
G3 H,CH
G4 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:04:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 206 TO ITERATE

100.0% PROCESSED 206 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3259 TO 4981
PROJECTED ANSWERS: 22 TO 418

L2 11 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:05:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3796 TO ITERATE

100.0% PROCESSED 3796 ITERATIONS 213 ANSWERS
SEARCH TIME: 00.00.01

L3 213 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 15:05:17 ON 13 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Dec 2006 VOL 145 ISS 25
FILE LAST UPDATED: 12 Dec 2006 (20061212/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 14 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:347021 CAPLUS Full-text
DOCUMENT NUMBER: 142:373972
TITLE: Silylated oxazolylethenyl-thiazolamine derivatives as potential cyclin-dependent kinase inhibitors for use in cancer and infection therapy
INVENTOR(S): Showell, Graham Andrew; Ruprah, Parminder Kaur; Walsh, Louise Marie
PATENT ASSIGNEE(S): Amedis Pharmaceuticals Ltd., UK
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035541	A1	20050421	WO 2004-GB4212	20041005

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-23470 A 20031007
GB 2004-5304 A 20040309
OTHER SOURCE(S): MARPAT 142:373972
GI



I

AB Compds. I (Z = NHCONH, NH, NHCOCH2, NHCO; R = (un)substituted piperidinyl, pyrimidinyl, pyridinyl, pyrazinyl, piperazinyl, morpholinyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 2-hydroxycyclohexyl) useful as cyclin-dependent kinase inhibitors in therapy of cancer, alopecia, neurodegenerative disorders, viral and fungal infections (no data) were prepd. by Wittig-Horner olefination of 2-amino-5-thiazolecarboxaldehyde by 5-silylated 2-diethoxyphosphinyloxazole, followed by optional acylation or carbamoylation of the thiazole-2-amine group. Satd. 1,2-ethanediyl analogs of I were also prepd. by Pd/C hydrogenation of the 1,2-ethenediyl moiety.
IT 849443-96-5P 849443-97-6P 849443-98-7P
849443-99-8P 849444-00-4P 849444-01-5P
849444-02-6P 849444-03-7P 849444-04-8P
849444-05-9P 849444-06-0P 849444-07-1P
849444-08-2P 849444-09-3P 849444-10-6P
849444-11-7P 849444-12-8P 849444-13-9P

849444-14-0P 849444-15-1P 849444-16-2P
849444-17-3P 849444-18-4P 849444-19-5P
849444-20-8P 849444-21-9P 849444-22-0P
849444-25-3P 849444-26-4P 849444-27-5P
849444-28-6P 849444-29-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of silylated oxazolyl-thiazolamine heterocyclic derivs. as possible cyclin-dependent kinase inhibitors in cancer and infection therapy)

RN 849443-96-5 CAPLUS
CN Urea, N-(1-methyl-4-piperidinyl)-N'-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849443-97-6 CAPLUS
CN 4-Pyrimidinamine, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849443-98-7 CAPLUS
CN Urea, N-4-piperidinyl-N'-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849443-99-8 CAPLUS
CN 2-Pyrimidinamine, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 849444-00-4 CAPLUS
CN 2-Pyridinamine, 4-methyl-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 849444-01-5 CAPLUS
CN Pyrazinamine, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 849444-02-6 CAPLUS
CN 2-Pyridinamine, 6-methyl-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 849444-03-7 CAPLUS
CN Acetamide, 2-[(1-methyl-4-piperidinyl)oxy]-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-04-8 CAPLUS
CN Urea, N-[6-(4-morpholinyl)-3-pyridinyl]-N'-[5-[2-[5-(trimethylsilyl)-2-

oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-05-9 CAPLUS
CN Urea, N-2-pyridinyl-N'-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 849444-06-0 CAPLUS
CN Urea, N-3-pyridinyl-N'-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-07-1 CAPLUS
CN 2-Piperazinecarboxamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-

thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-08-2 CAPLUS
CN Urea, N-4-pyridinyl-N'-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-09-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(hydroxymethyl)-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-10-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-11-7 CAPLUS
CN Urea, N-(2-hydroxycyclohexyl)-N'-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-12-8 CAPLUS
CN 4-Piperidineacetamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-13-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-14-0 CAPLUS
CN 4-Piperidineacetamide, 1-methyl-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-15-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-methyl-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-16-2 CAPLUS
CN 1H-Imidazole-4-acetamide, 1-methyl-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-17-3 CAPLUS
CN 3-Pyridineacetamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-18-4 CAPLUS
CN Acetamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-19-5 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-20-8 CAPLUS
CN 4-Piperidinecarboxamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-21-9 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N'-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-22-0 CAPLUS
CN 3-Piperidinecarboxamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-25-3 CAPLUS
CN 1-Piperazineacetamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-26-4 CAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-27-5 CAPLUS
CN 4-Morpholineacetamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-28-6 CAPLUS
CN 1-Piperidineacetamide, N-[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 849444-29-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[5-[2-[5-(trimethylsilyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:158642 CAPLUS Full-text

Current App.

Current app.

DOCUMENT NUMBER: 142:254629
TITLE: Preparation of thiazole and oxazole derivatives as probe for amyloid accumulation diseases and as staining agents for neurofibrillary change
INVENTOR(S): Kudo, Yukitsuka; Suzuki, Masako; Suemoto, Takahiro; Okamura, Nobuyuki; Shiomitsu, Tsuyoshi; Shimazu, Hiroshi
PATENT ASSIGNEE(S): BF Research Institute, Inc., Japan
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016888	A1	20050224	WO 2004-JP11546	20040811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005016384	A1	20050224	WO 2003-JP315229	20031128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004265174	A1	20050224	AU 2004-265174	20040811
CA 2500358	AA	20050224	CA 2004-2500358	20040811
EP 1655287	A1	20060510	EP 2004-771531	20040811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004013556	A	20061017	BR 2004-13556	20040811
CN 1867552	A	20061122	CN 2004-80029803	20040811
US 2006018825	A1	20060126	US 2005-527398	20050311
NO 2006001169	A	20060511	NO 2006-1169	20060313

PRIORITY APPLN. INFO.:		
JP 2003-293056	A	20030813
WO 2003-JP15229	A	20031128
WO 2003-JP315229	A	20031128
WO 2004-JP11546	W	20040811

OTHER SOURCE(S): MARPAT 142:254629
GI



I

II

III

AB The title compds. I [wherein A = (un)substituted (hetero)arylene; R1 and R2 = independently H or alkyl; R4 and R5 = independently H, halo, OH, etc.; D = NH, O, S, or CH=CH; E = N or CH; m = 0-4; But m = 2-4 when A is phenylene] and II [wherein A = heteroarylene; R1 and R2 = independently H or alkyl; R6 = halo, OH, CO2H, etc.; n = 0-4], or salts or solvates thereof are prepd. for diagnosing diseases with amyloid .beta.-protein accumulation, and as a staining agent specific to amyloid .beta.-protein and treating and preventing diseases with amyloid .beta.-protein accumulation. It is also intended to provide a probe for neurofibrillary changes and a staining agent for neurofibrillary changes. For example, the compd. III was prepd. in a multi-step synthesis, and used for staining test. I and II are useful for diagnosing Alzheimer's disease.

IT 682763-75-3P 682763-77-5P 682763-78-6P
682763-79-7P 845647-80-5P 846055-70-7P
846055-71-8P 846055-72-9P 846055-73-0P
846055-74-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of thiazole and oxazole derivs. as probe for amyloid accumulation diseases and as staining agents for neurofibrillary change)

RN 682763-75-3 CAPLUS

CN 2-Thiazolamine, 5-[2-(2-benzoxazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 682763-77-5 CAPLUS

CN 2-Oxazolamine, 5-[2-(2-benzoxazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 682763-78-6 CAPLUS
CN 2-Thiazolamine, 5-[2-(2-benzothiazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 682763-79-7 CAPLUS
CN 2-Thiazolamine, 5-[2-(4,5-dimethyl-2-oxazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 845647-80-5 CAPLUS
CN 2-Thiazolamine, 5-[2-[6-(2-fluoroethoxy)-2-benzoxazolyl]ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 846055-70-7 CAPLUS
CN Ethanol, 2-[[2-[2-[2-(dimethylamino)-5-oxazolyl]ethenyl]-4-oxazolyl]oxy]-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)



RN 846055-71-8 CAPLUS
CN Ethanol, 2-[[2-[2-[2-(dimethylamino)-5-thiazolyl]ethenyl]-6-benzoxazolyl]oxy]-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)



RN 846055-72-9 CAPLUS
CN 2-Thiazolamine, N,N-dimethyl-5-[2-[6-(tributylstannyl)-2-benzoxazolyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 846055-73-0 CAPLUS
CN Ethanol, 2-[[2-[2-[2-(dimethylamino)-5-thiazolyl]ethenyl]-6-benzothiazolyl]oxy]-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)



RN 846055-74-1 CAPLUS
CN Ethanol, 2-[[2-[2-[2-(dimethylamino)-5-oxazolyl]ethenyl]-4-methyl-5-oxazolyl]methoxy]-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)



IT 845647-78-1P 845647-79-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of thiazole and oxazole derivs. as probe for amyloid accumulation diseases and as staining agents for neurofibrillary change)
RN 845647-78-1 CAPLUS
CN 2-Thiazolamine, 5-[2-[6-(methoxymethoxy)-2-benzoxazolyl]ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 845647-79-2 CAPLUS
CN 6-Benzoxazolol, 2-[2-[2-(dimethylamino)-5-thiazolyl]ethenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:158564 CAPLUS Full-text
DOCUMENT NUMBER: 142:233352
TITLE: Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
INVENTOR(S): Kudo, Yukitsuka; Suzuki, Masako; Suemoto, Takahiro; Okamura, Nobuyuki; Shiomitsu, Tsuyoshi; Shimazu, Hiroshi
PATENT ASSIGNEE(S): BF Research Institute, Inc., Japan
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016384	A1	20050224	WO 2003-JP15229	20031128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003304416	A1	20050307	AU 2003-304416		20031128
AU 2004265174	A1	20050224	AU 2004-265174		20040811
CA 2500358	AA	20050224	CA 2004-2500358		20040811
WO 2005016888	A1	20050224	WO 2004-JP11546		20040811

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1655287	A1	20060510	EP 2004-771531		20040811

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

BR 2004013556	A	20061017	BR 2004-13556		20040811
CN 1867552	A	20061122	CN 2004-80029803		20040811
US 2006018825	A1	20060126	US 2005-527398		20050311
NO 2006001169	A	20060511	NO 2006-1169		20060313
PRIORITY APPLN. INFO.:			JP 2003-293056	A	20030813
			WO 2003-JP15229	W	20031128
			WO 2003-JP315229	A	20031128
			WO 2004-JP11546	W	20040811

Cancel

AB It is intended to provide a compd. having a high specificity for amyloid .beta. protein which is usable in diagnosing a disease with amyloid .beta. protein deposit, a staining agent specific for amyloid .beta. protein and treating and preventing a disease with amyloid .beta. protein deposit. It is also intended to provide a probe for a neurofibril change and a staining agent for a neurofibril change.

IT 682763-75-3P 682763-78-6P 682763-79-7P
845647-80-5P
RL: ADV (Adverse effect, including toxicity); DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change)

RN 682763-75-3 CAPLUS
CN 2-Thiazolamine, 5-[2-(2-benzoxazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 682763-78-6 CAPLUS
CN 2-Thiazolamine, 5-[2-(2-benzothiazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA

INDEX NAME)



RN 682763-79-7 CAPLUS
CN 2-Thiazolamine, 5-[2-(4,5-dimethyl-2-oxazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 845647-80-5 CAPLUS
CN 2-Thiazolamine, 5-[2-[6-(2-fluoroethoxy)-2-benzoxazolyl]ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 845647-78-1P 845647-79-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change)
RN 845647-78-1 CAPLUS
CN 2-Thiazolamine, 5-[2-[6-(methoxymethoxy)-2-benzoxazolyl]ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 845647-79-2 CAPLUS
CN 6-Benzoxazolol, 2-[2-[2-(dimethylamino)-5-thiazolyl]ethenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:846743 CAPLUS Full-text
DOCUMENT NUMBER: 142:6153
TITLE: First hyperpolarizabilities of nonlinear optical compounds: Susceptibility in donor-acceptor stilbene analogs
AUTHOR(S): Park, Gyoosoon; Jung, Woo Sik; Ra, Choon Sup
CORPORATE SOURCE: Department of Chemistry, Kookmin University, Seoul, 136-702, S. Korea
SOURCE: Bulletin of the Korean Chemical Society (2004), 25(9), 1427-1429
CODEN: BKCSDE; ISSN: 0253-2964
PUBLISHER: Korean Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The authors have studied the first hyperpolarizabilities of 138 chromophores (1-12)stilbene and heteroarom. analogs by ab initio method. The results reveal a good linear relation exists between the first hyperpolarizability (P) and gas-phase substituent consts. (.sigma.+gas) as known before. The susceptibility (.rho.) of the .beta. to the donor strength is quite characteristic of the conjugated bridges. Results provides a systematic account of the nature of the heteroaroms. and the substitution pattern at the conjugated bridges on mol. hyperpolarizability of donor-acceptor stilbene chromophores and suggests a practical guideline for developing heteroarom. - NLO materials.

IT 791853-28-6 791853-29-7 791853-52-6
791853-54-8
RL: PRP (Properties)
(first hyperpolarizabilities of nonlinear optical compds. and susceptibility in donor-acceptor stilbene analogs)

RN 791853-28-6 CAPLUS
CN 2-Oxazolamine, 5-[2-(5-nitro-2-oxazolyl)ethenyl]- (9CI) (CA INDEX NAME)



RN 791853-29-7 CAPLUS
CN 2-Oxazolamine, N,N-dimethyl-5-[2-(5-nitro-2-oxazolyl)ethenyl]- (9CI) (CA INDEX NAME)



RN 791853-52-6 CAPLUS
CN 2-Thiazolamine, 5-[2-(5-nitro-2-thiazolyl)ethenyl]- (9CI) (CA INDEX NAME)



RN 791853-54-8 CAPLUS
CN 2-Thiazolamine, N,N-dimethyl-5-[2-(5-nitro-2-thiazolyl)ethenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:354902 CAPLUS Full-text
DOCUMENT NUMBER: 140:352748
TITLE: Heterocyclic compounds for use as diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
INVENTOR(S): Doh-ura, Katsumi; Kudo, Yukitsuka; Sawada, Tohru
PATENT ASSIGNEE(S): BF Research Institute, Inc., Japan
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

102(e) same assignee different inventor

102(e)

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004035522	A1	20040429	WO 2003-JP11056		20030829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2496633	AA	20040429	CA 2003-2496633		20030829
AU 2003261834	A1	20040504	AU 2003-261834		20030829
EP 1547996	A1	20050629	EP 2003-808871		20030829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2005260126	A1	20051124	US 2005-524691		20050215
PRIORITY APPLN. INFO.:			JP 2002-255013	A	20020830
			JP 2002-255014	A	20020830
			JP 2002-255015	A	20020830
			JP 2003-73344	A	20030318
			WO 2003-JP11056	W	20030829

OTHER SOURCE(S): MARPAT 140:352748
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are compds. such as benzoxazole, benzothiazole, benzimidazole, quinoline, pyridine, benzene, thiazole, imidazole, pyrrole, furan, and benzoxazole derivs. represented by the general formula (I) or (II) or salts or solvates thereof [wherein D = NR', S, O, CH:CH, CH2; wherein R' = H, C1-4 alkyl, halo-C1-4 alkyl, Ph; E = N, CH; Q = N, CRb; Ra, Rb, R1, R2 = H, C1-4 alkyl, halo, HO, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, NO2, C1-4 alkoxy, CO2H, SO3H, halo-C1-4 alkyl; m = an integer of 0-4; or R1 and R2 together form each (un)substituted benzene or naphthalene ring; R3 = groups listed for Ra, Rb, R1, or R2, Q-Q3, NHCORx; wherein Rx = groups listed for Ra, Rb, R1, or R2, N:CH-allyl; A = R4-Q7, thiazole-2,4-diyl, oxazole-2,4-diyl, etc.; Rz = groups listed for Ra, Rb, R1, or R2; X, Y = N, CH; Z = O, S, CH2, N-CpH2p+1; wherein p = an integer of 0-4] which are useful in the diagnosis, prevention, and/or treatment of diseases such as prion diseases or transmissible spongiform encephalopathies (TSEs) with accumulation of prion protein or in specific staining of prion protein contained in a specimen for imaging by PET or SPECT using positron or .gamma.-ray emitting radionuclides. For example, 2-[2-(4-fluorophenyl)ethenyl]benzoxazole and 2-[2-(2-hydroxy-4-methylaminophenyl)ethenyl]quinoline inhibited the abnormal prion protein in mouse neuroblastoma ScN2a cells infected with sheep scrapie (sheep prion) with IC50 of 0.8 nM.

IT 682763-75-3 682763-77-5 682763-78-6
682763-79-7
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological

study); USES (Uses)
(heterocyclic compds. for use as diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein imaging by PET or SPECT using radionuclides)

RN 682763-75-3 CAPLUS
CN 2-Thiazolamine, 5-[2-(2-benzoxazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 682763-77-5 CAPLUS
CN 2-Oxazolamine, 5-[2-(2-benzoxazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 682763-78-6 CAPLUS
CN 2-Thiazolamine, 5-[2-(2-benzothiazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 682763-79-7 CAPLUS
CN 2-Thiazolamine, 5-[2-(4,5-dimethyl-2-oxazolyl)ethenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:182368 CAPLUS Full-text
DOCUMENT NUMBER: 140:229401

102(e) NO Common inventor and Assignee

TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands

INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph

PATENT ASSIGNEE(S): Gpc Biotech Inc., USA; Gpc Biotech AG

SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

102(e)

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004043388	A1	20040304	US 2002-234985		20020903
US 7135550	B2	20061114			
US 2003165873	A1	20030904	US 2002-91177		20020304
US 2004266854	A1	20041230	US 2004-820453		20040407

PRIORITY APPLN. INFO.:

US 2001-272932P	P	20010302
US 2001-278233P	P	20010323
US 2001-329437P	P	20011015
US 2002-91177	A2	20020304
US 2001-336962P	P	20011203
WO 2002-US6677	A2	20020304
US 2002-234985	A2	20020903
WO 2002-US33052	A2	20021015
US 2003-460921P	P	20030407
US 2003-531872P	P	20031223

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Prepn. of compds., e.g a methotrexate moiety linked by a polyethylene gycol moiety to dexamethasone, is described.

IT 666838-34-2D, conjugates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 666838-34-2 CAPLUS

CN Acetamide, N-[5-[2-(5-ethyl-2-oxazolyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

check spec

possible



D E

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:66145 CAPLUS Full-text
DOCUMENT NUMBER: 132:222193
TITLE: Thiazole and Thiophene Analogues of Donor-Acceptor Stilbenes: Molecular Hyperpolarizabilities and Structure-Property Relationships
AUTHOR(S): Breitung, Eric M.; Shu, Ching-Fong; McMahon, Robert J.
CORPORATE SOURCE: Department of Chemistry, University of Wisconsin, Madison, WI, 53706-1369, USA
SOURCE: Journal of the American Chemical Society (2000), 122(6), 1154-1160
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors calc. the 1st hyperpolarizability (.beta.) of several thiazole and thiophene analogs of donor-acceptor stilbene compds. using the ZINDO (sum-over-states) formalism. Because of the inherent dipolar nature of thiazole, in which C2 is electron-poor and C5 is electron-rich, the relative orientation of the thiazole subunit in the dipolar chromophore dramatically affects the nonlinear optical properties. In the mismatched case, the dipole of the thiazole ring opposes the mol. dipole created by the donor-acceptor substituents, while in the matched case, the dipole of the thiazole ring reinforces the mol. dipole. The hyperpolarizability of the mismatched monothiazole I (.beta..mu. = 68 .times. 10-30 cm5 esu-1) exceeds that of stilbene II (.beta..mu. = 34 .times. 10-30 cm5 esu-1) but is smaller than that of monothiophene III (.beta..mu. = 90 .times. 10-30 cm5 esu-1). By contrast, the hyperpolarizability of the matched monothiazole IV (.beta..mu. = 177 .times. 10-30 cm5 esu-1) exceeds not only that of the mismatched monothiazole I, but also that of monothiophene III. Substituting thiazole for both aryl rings of stilbene produces very large hyperpolarizabilities in the matched-matched case (e.g., bis-thiazole V, .beta..mu. = 254 .times. 10-30 cm5 esu-1). The nonlinear optical response of heterocyclic analogs of donor-acceptor stilbene derivs. is discussed in terms of the difference in arom. delocalization energy between Ph, thiophene, and thiazole, the electronic nature of the heteroarom. rings, and conformational factors.

IT 261000-35-5 261000-44-6
RL: PRP (Properties)
(thiazole and thiophene analogs of donor-acceptor stilbenes: mol. hyperpolarizabilities and structure-property relationships)

RN 261000-35-5 CAPLUS
CN Ethenetricarbonitrile, [2-[2-[2-(diethylamino)-5-thiazolyl]ethenyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)



Not match.

RN 261000-44-6 CAPLUS
CN Propanedinitrile, [[2-[2-[2-(diethylamino)-5-thiazolyl]ethenyl]-5-thiazolyl]methylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:811221 CAPLUS Full-text
DOCUMENT NUMBER: 132:35695
TITLE: Preparation of carbon substituted aminothiazole inhibitors of cyclin dependent kinases
INVENTOR(S): Rawlins, David B.; Kimball, S. David; Misra, Raj N.; Kim, Kyoung S.; Webster, Kevin R.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965884	A1	19991223	WO 1999-US13034	19990611
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6407124	B1	20020618	US 1999-329616	19990610
CA 2332325	AA	19991223	CA 1999-2332325	19990611
AU 9944311	A1	20000105	AU 1999-44311	19990611
AU 768751	B2	20040108		
EP 1087951	A1	20010404	EP 1999-927401	19990611
EP 1087951	B1	20050209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518380	T2	20020625	JP 2000-554710	19990611
AT 288904	E	20050215	AT 1999-927401	19990611

ES 2237919	T3	20050801	ES 1999-927401		19990611
US 2002165259	A1	20021107	US 2002-112133		20020329
US 6720347	B2	20040413			
PRIORITY APPLN. INFO.:			US 1998-89747P	P	19980618
			US 1999-329616	A3	19990610
			WO 1999-US13034	W	19990611

OTHER SOURCE(S): MARPAT 132:35695

GI



I



II

AB The title compds. [I; R1 = R2, COR3, CONH2, etc.; R2 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; A = (CR7R8)m(CR5R6)nR4 (wherein n = 0-2; m = 1-2 but both n and m cannot be 2), (CR7R8)jY(CR5R6)iR4 (i, j = 0-1 but cannot both be 1; Y = (un)substituted alkene, alkyne, any 2 adjacent carbon atoms of a cycloalkyl or cycloheteroalkyl ring of 3-7 atoms); R4 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R5-R8 = H, alkyl, cycloalkyl, etc.], protein kinase inhibitors (no data) which are useful in the treatment of proliferative diseases, for example, cancer, inflammation, and arthritis, and also in the treatment of Alzheimer's disease, and cardiovascular disease, were prepd. E.g., a multi-step synthesis of (E)-II, starting with 2-aminothiazol-5-ylcarboxaldehyde, was given.

IT 252660-50-7P 252661-91-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of carbon substituted aminothiazole inhibitors of cyclin dependent kinases)

RN 252660-50-7 CAPLUS

CN Acetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-91-9 CAPLUS

CN Carbamic acid, [5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 252660-52-9P 252660-54-1P 252660-56-3P
252660-57-4P 252660-58-5P 252660-59-6P
252660-60-9P 252660-61-0P 252660-62-1P
252660-63-2P 252660-64-3P 252660-65-4P
252660-66-5P 252660-73-4P 252660-82-5P
252660-83-6P 252660-90-5P 252660-91-6P
252660-92-7P 252660-95-0P 252660-96-1P
252660-97-2P 252660-98-3P 252661-00-0P
252661-02-2P 252661-03-3P 252661-04-4P
252661-05-5P 252661-06-6P 252661-07-7P
252661-08-8P 252661-09-9P 252661-10-2P
252661-11-3P 252661-12-4P 252661-13-5P
252661-14-6P 252661-15-7P 252661-16-8P
252661-17-9P 252661-18-0P 252661-19-1P
252661-20-4P 252661-21-5P 252661-22-6P
252661-23-7P 252661-24-8P 252661-25-9P
252661-26-0P 252661-27-1P 252661-28-2P
252661-29-3P 252661-31-7P 252661-32-8P
252661-33-9P 252661-34-0P 252661-35-1P
252661-36-2P 252661-37-3P 252661-38-4P
252661-39-5P 252661-40-8P 252661-41-9P
252661-42-0P 252661-43-1P 252661-44-2P
252661-45-3P 252661-46-4P 252661-47-5P
252661-48-6P 252661-49-7P 252661-53-3P
252661-55-5P 252661-56-6P 252661-58-8P
252661-59-9P 252661-60-2P 252661-61-3P
252661-62-4P 252661-64-6P 252661-65-7P
252661-66-8P 252661-67-9P 252661-68-0P
252661-69-1P 252661-70-4P 252661-71-5P
252661-72-6P 252661-73-7P 252661-74-8P
252661-75-9P 252661-76-0P 252661-77-1P
252661-78-2P 252661-79-3P 252661-80-6P
252661-81-7P 252661-82-8P 252661-83-9P
252661-84-0P 252661-85-1P 252661-86-2P
252661-87-3P 252661-88-4P 252661-89-5P
252661-90-8P 252661-92-0P 252661-93-1P
252661-94-2P 252661-95-3P 252661-96-4P
252661-97-5P 252661-98-6P 252661-99-7P
252662-00-3P 252662-01-4P 252662-02-5P
252662-03-6P 252662-04-7P 252662-05-8P
252662-06-9P 252662-07-0P 252662-08-1P
252662-09-2P 252662-10-5P 252662-11-6P
252662-12-7P 252662-13-8P 252662-14-9P
252662-15-0P 252662-16-1P 252662-17-2P
252662-18-3P 252662-19-4P 252662-20-7P
252662-21-8P 252662-22-9P 252662-26-3P
252662-27-4P 252662-28-5P 252662-29-6P
252662-31-0P 252662-33-2P 252662-34-3P
252662-35-4P 252662-36-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of carbon substituted aminothiazole inhibitors of cyclin dependent kinases)

RN 252660-52-9 CAPLUS
CN Benzeneacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-54-1 CAPLUS
CN 2-Pyridinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 252660-56-3 CAPLUS
CN Acetamide, N-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-57-4 CAPLUS
CN Carbamic acid, [5-[(1E)-2-[5-(1-methylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-58-5 CAPLUS
CN 3-Pyridineacetamide, N-[5-[(1E)-2-[5-(1-methylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-59-6 CAPLUS
CN Acetamide, N-[5-[(1E)-2-[5-(1-methylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-60-9 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-61-0 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-62-1 CAPLUS
CN 3-Pyridineacetamide, N-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-63-2 CAPLUS
CN 3-Pyridineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-64-3 CAPLUS
CN 2-Naphthaleneacetamide, N-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-65-4 CAPLUS
CN 2-Naphthaleneacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-66-5 CAPLUS
CN Benzeneacetamide, N-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-73-4 CAPLUS
CN Acetamide, N-[5-[(1Z)-2-bromo-2-[5-(1-methylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-82-5 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-[5-[(1E)-2-[5-(1-methylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-83-6 CAPLUS
CN Propanamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-90-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-91-6 CAPLUS
CN 1-Piperazineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-

oxazolyl]ethenyl]-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-92-7 CAPLUS
CN 4-Morpholineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-95-0 CAPLUS
CN Acetamide, N-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]-2-fluoroethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-96-1 CAPLUS
CN 1H-Imidazole-4-acetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-97-2 CAPLUS
CN 1-Piperazineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252660-98-3 CAPLUS
CN Benzoic acid, 4-[2-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-00-0 CAPLUS
CN Acetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-2-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-02-2 CAPLUS
CN Acetamide, N-[5-[(1E)-2-(5-phenyl-2-oxazolyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-03-3 CAPLUS
CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



102(b)

RN 252661-04-4 CAPLUS
CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-05-5 CAPLUS
CN Urea, N-cyclohexyl-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-06-6 CAPLUS
CN Benzamide, 4-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-07-7 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-08-8 CAPLUS
CN Urea, N-1,3-benzodioxol-5-yl-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-09-9 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-10-2 CAPLUS
CN Urea, N-(2,6-dichloro-4-methoxyphenyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-11-3 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-2-pyridinyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252661-12-4 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-13-5 CAPLUS
CN Benzamide, 3-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-14-6 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-15-7 CAPLUS
CN Benzamide, 3-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-16-8 CAPLUS
CN Benzoic acid, 4-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-17-9 CAPLUS
CN Benzamide, 4-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-18-0 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-19-1 CAPLUS
CN Benzoic acid, 5-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]-2-(4-morpholinyl)-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-20-4 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-21-5 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(2-methylcyclohexyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-22-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-23-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-24-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-25-9 CAPLUS
CN Urea, N-cyclohexyl-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-26-0 CAPLUS
CN Urea, N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-27-1 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-3-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-28-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-4-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-29-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-31-7 CAPLUS
CN Benzoic acid, 4-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-32-8 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-33-9 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-4-pyridinyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-34-0 CAPLUS
CN Benzoic acid, 4-[2-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-35-1 CAPLUS
CN Urea, N-(2,3-dihydro-1,1-dioxido-3-oxo-1,2-benzisothiazol-6-yl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-36-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-3-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-37-3 CAPLUS
CN Urea, N-(2-chloro-4-hydroxyphenyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-38-4 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-39-5 CAPLUS
CN Urea, N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-40-8 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252661-41-9 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(1,2,3,4-tetrahydro-1,4-dioxo-6-phthalazinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-42-0 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-[(1R,2R)-2-hydroxycyclohexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 252661-43-1 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 252661-44-2 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 252661-45-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-46-4 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]-2-fluoroethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-47-5 CAPLUS
CN 4-Piperidineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-48-6 CAPLUS
CN Urea, N-(4-cyanophenyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-49-7 CAPLUS
CN Urea, N-(6-chloro-3-pyridinyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-53-3 CAPLUS
CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-55-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252661-56-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252661-58-8 CAPLUS
CN Propanamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-3-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-59-9 CAPLUS
CN 4-Piperidineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-60-2 CAPLUS
CN Benzeneacetamide, 4-[2-(diethylamino)ethoxy]-N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-61-3 CAPLUS
CN Benzeneacetamide, N-[5-[(1E)-2-[5-(1-methylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-62-4 CAPLUS
CN Urea, N-(3,5-dichloro-4-pyridinyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-64-6 CAPLUS
CN Glycine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-65-7 CAPLUS
CN Acetamide, 2-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-66-8 CAPLUS
CN 1-Propanol, 3-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-67-9 CAPLUS

CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



(102b)

RN 252661-68-0 CAPLUS
CN Formamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-69-1 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-3,4-dihydroxy-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 252661-70-4 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-71-5 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(2,6-dimethyl-1-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-72-6 CAPLUS
CN Glycine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-73-7 CAPLUS
CN Glycine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-74-8 CAPLUS
CN Acetonitrile, [[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-75-9 CAPLUS
CN 1H-Imidazole-1-acetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-76-0 CAPLUS
CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-phenyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-77-1 CAPLUS
CN 1H-Imidazole-4-acetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-78-2 CAPLUS
CN 1H-Imidazole-4-propanamide, .alpha.-(acetylamino)-N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-79-3 CAPLUS
CN 1H-Benzimidazole-2-propanamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-80-6 CAPLUS
CN Carbamic acid, [(1S)-2-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]-1-[(1-methyl-1H-imidazol-4-yl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 252661-81-7 CAPLUS
CN 1H-Imidazole-4-propanamide, .alpha.-amino-N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 252661-82-8 CAPLUS
CN 1H-Imidazole-5-propanamide, .alpha.-amino-N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-1-methyl-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 252661-83-9 CAPLUS
CN 1H-Imidazole-4-propanamide, .alpha.-amino-N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-1-methyl-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 252661-84-0 CAPLUS
CN Ethanol, 2-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



(02Ch)

RN 252661-85-1 CAPLUS
CN 1-Butanol, 4-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



(02Ch)

RN 252661-86-2 CAPLUS
CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



(02Ch)

RN 252661-87-3 CAPLUS
CN 2-Butanol, 4-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-88-4 CAPLUS
CN 1-Propanol, 3-[[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-89-5 CAPLUS
CN 1,5-Pentanediamine, N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-90-8 CAPLUS
CN 1,3,5-Triazin-2(1H)-one, 4-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]-6-propoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 252661-92-0 CAPLUS

CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-93-1 CAPLUS

CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-94-2 CAPLUS

CN 2-Thiazolamine, N-(4-chlorophenyl)-5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-95-3 CAPLUS

CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-96-4 CAPLUS
CN 3-Pyridinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-97-5 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252661-98-6 CAPLUS
CN Pyrazinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252661-99-7 CAPLUS
CN 4-Pyridinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-00-3 CAPLUS
CN 2-Thiazolamine, N-(3-chlorophenyl)-5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-01-4 CAPLUS
CN 3-Pyridineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-02-5 CAPLUS
CN 1H-Imidazole-1-acetamide, N-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-03-6 CAPLUS
CN Propanamide, N-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-04-7 CAPLUS
CN 2-Pyrimidinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252662-05-8 CAPLUS
CN 3-Pyridineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-, 1-oxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-06-9 CAPLUS
CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-07-0 CAPLUS
CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-08-1 CAPLUS
CN 3-Isoquinolinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252662-09-2 CAPLUS
CN 4-Pyrimidinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 252662-10-5 CAPLUS

CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-11-6 CAPLUS

CN 2-Pyridinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-, 1-oxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-12-7 CAPLUS

CN 1,3-Benzenediamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-13-8 CAPLUS
CN 4-Pyridinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-, 1-oxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-14-9 CAPLUS
CN Benzamide, 4-[[[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-15-0 CAPLUS
CN 3-Pyridineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-.alpha.-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-16-1 CAPLUS
CN Urea, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-N'-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-17-2 CAPLUS
CN Benzeneacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-4-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-18-3 CAPLUS
CN 3-Pyridazinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252662-19-4 CAPLUS
CN 3-Pyridineacetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-.alpha.,2-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-20-7 CAPLUS
CN 2,6-Pyridinediamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252662-21-8 CAPLUS
CN 2-Thiazolamine, N-cyclopropyl-5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



(024)

RN 252662-22-9 CAPLUS
CN Pyridinium, 3-[2-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-26-3 CAPLUS
CN 1H-Pyrazole-1-acetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-27-4 CAPLUS
CN 1H-Imidazole-1-acetamide, 4,5-dichloro-N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-28-5 CAPLUS
CN 1H-Imidazole-1-acetamide, 4,5-dicyano-N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-29-6 CAPLUS
CN 1H-Imidazole-1-acetamide, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-31-0 CAPLUS
CN 2-Pyridinamine, N-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252662-33-2 CAPLUS
CN 4-Pyrimidinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-6-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252662-34-3 CAPLUS
CN Benzenemethanol, 3-[[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 252662-35-4 CAPLUS
CN 2-Pyridinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 252662-36-5 CAPLUS
CN 2-Pyridinamine, N-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-2-thiazolyl]-6-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT 252662-38-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of carbon substituted aminothiazole inhibitors of cyclin dependent kinases)
RN 252662-38-7 CAPLUS
CN 2-Thiazolamine, 5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



(0206)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:616096 CAPLUS Full-text
DOCUMENT NUMBER: 125:261111
TITLE: Silver halide photographic material and rapid development process
INVENTOR(S): Honda, Mari; Oonishi, Akira; Tanaka, Tatsuo; Komamura, Tawara
PATENT ASSIGNEE(S): Konishiroku Photo Ind., Japan; Konica Minolta Holdings Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 41 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08179467	A2	19960712	JP 1994-323063	19941226
JP 3467658	B2	20031117		

PRIORITY APPLN. INFO.: JP 1994-323063 19941226
GI



I

AB The Ag halide photog. material has .gtoreq.1 nonphotosensitive hydrophilic colloidal layer on a support contg. a dispersion of solid dye microparticle whose chem. formula is represented by I (D = N, N+R1; R1 = H, alkyl, alkenyl, O+, S+; Z1 = nonmetallic at. group forming heterocyclyl; Q = aryl, heterocyclyl; X- = anion; k = 0, 1;m = 0, 1; n = 1-3; L1-4 = methine). The process is carried out in the total processing time of .ltoreq.90 s. The photog. material showed little fogging and exhibited image sharpness.

IT 182012-00-6
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(dispersion of dye particles in silver halide photog. material)

RN 182012-00-6 CAPLUS
CN Benzoxazolium, 2-[2-[2-[bis(2-hydroxyethyl)amino]-5-thiazolyl]-3,3,3-trifluoro-1-propenyl]-3-ethyl-5,6-dihydroxy-, perchlorate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 182011-99-0
CMF C19 H21 F3 N3 O5 S



CM 2

CRN 14797-73-0
CMF Cl O4



102(6).

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1974:431848 CAPLUS Full-text
DOCUMENT NUMBER: 81:31848
TITLE: Sensitized electrophotographic layers
INVENTOR(S): Oehlschlaeger, Hans; Riester, Oskar; Ghys, Theofiel H.; Verhille, Karel E.; Vanheertum, Johannes J.
PATENT ASSIGNEE(S): Agfa-Gevaert A.-G.
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2214055	A1	19730927	DE 1972-2214055	19720323
BE 796792	A2	19730917	BE 1973-1004896	19730315
US 3881926	A	19750506	US 1973-342872	19730319
GB 1401133	A	19750723	GB 1973-13277	19730320
CA 984651	A1	19760302	CA 1973-166696	19730321
IT 979930	A	19740930	IT 1973-48929	19730322
CH 582368	A	19761130	CH 1973-4191	19730322
FR 2177095	A1	19731102	FR 1973-10544	19730323
JP 49008237	A2	19740124	JP 1973-32818	19730323

PRIORITY APPLN. INFO.: DE 1972-2214055 A 19720323
GI For diagram(s), see printed CA Issue.
AB Cyanine dyes (I, II, III; R = NO2, acyl; R1, R2 = aryl, satd. or unsatd. aliph.; R3 = H, aryl, satd. or unsatd. aliph.; R4 = SR7, NR8R9 where R7,R8,R9 = aliph. or R8R9 together completing a 5- or 6-member heterocyclic ring; n, p = 0, 1; M = 0-3 interger; X- = anion; Z1, Z2 = atom groups for completing a 5- or 6-member heterocyclic ring.) are used as spectral sensitizers for zinc oxide and org. photoconductors in electrophotog. Thus, 0.1 g IV as 0.1% soln. in DMF was added to a photoconductive compn. prepd. from ZnO 20, acrylic

copolymer 4.5 g, PhMe 20, EtOAc 11 and 10% tetrachlorophthalic anhydride in EtOH 0.66 ml., coated on a baryta paper (25 g ZnO/m2), charged, exposed to an incandescent lamp (2280 lx) through a stepwedge for 15 sec to give 25 steps with a max. sensitivity at 555 nm. as compared to only 14 steps for IV-free control.

IT 42905-72-6
RL: USES (Uses)
(electrophotog. sensitizer)

RN 42905-72-6 CAPLUS

CN Benzothiazolium, 2-[1-cyano-2-[2-(dimethylamino)-4-phenyl-5-thiazolyl]ethenyl]-3-ethyl-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 48221-76-7
CMF C23 H21 N4 S2



CM 2

CRN 14797-73-0
CMF Cl O4



L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1974:126790 CAPLUS Full-text
DOCUMENT NUMBER:	80:126790
TITLE:	Sensitized electrophotographic layers
INVENTOR(S):	Oehlschlaeger, Hans; Riester, Oskar; Ghys, Theofiel H.; Verhille, Karel E.; Vanheertum, Johannes J.
PATENT ASSIGNEE(S):	Agfa-Gevaert A.-G.
SOURCE:	Ger. Offen., 23 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

DE 2214054	A1	19730927	DE 1972-2214054		19720323
BE 796791	A2	19730917	BE 1973-1004895		19730315
US 3923507	A	19751202	US 1973-342886		19730319
US 342886	A1	19750128			
IT 980437	A	19740930	IT 1973-48930		19730321
GB 1387234	A	19750312	GB 1973-13531		19730321
CA 995949	A1	19760831	CA 1973-166695		19730321
CH 571240	A	19751231	CH 1973-4190		19730322
JP 49008238	A2	19740124	JP 1973-32819		19730323

PRIORITY APPLN. INFO.: DE 1972-2214054 A 19720323

GI For diagram(s), see printed CA Issue.

AB Cyanine dyes (I or II; R1 = Ph, cyclohexyl or a C .ltoreq.6 aliphatic group contg. Ph, OH, halogen, CO2h, SO3H, carboxamido, carbalkoxy, SO4, S2O3, sulfonamido or PO4; R2, R4, R8H, Me, Et or Ph; R3 = SR9 or NR10R11 where R9, R10, R11 = Me, Et, or Ph or R10R11 form a pyrrolidine, piperidine, morpholine, or thiomorpholine ring; R5, R6, R7 = Me, Et, or Ph, carbethoxy or R5R6 complete a benzene or naphthalene ring; n, m = 0 or 1; X- = halide, ClO4-, MeSO3-, or p-MeC6H4SO3-; Z = a group necessary to complete a 5- or 6-membered heterocyclic ring) with reduced stain formation are used as sensitizers in electrophotog. layers. Thus, 2-methyl-3-ethylbenzothiazolium tosylate 3.3, 2-(methylthio)-4- methylthiazole-5-carboxaldehyde 1.7 g and Et3N 1.2 ml were refluxed in 10 ml (AcO)2O. After addn of KI, 1.7 g III (m. 226.degree. decomp.) was obtained. A soln. of 0.05 g III and 4 g 1-ethyl-3-phenyl-7-(diethylamino)- 2(1H)-quinoline in 100 ml (1:1) CH2Cl2-Me2CO mixt. was coated on an Al-backed paper support to a dry thickness of 2 g/m2, corona charged to -6000 V, exposed to 2000 lx for 15 sec at 25 cm, and developed, showing a relative sensitivity of 2500 vs. 100 for a III-free control.

IT 41474-55-9
RL: USES (Uses)
(electrophotographic sensitizer, for quinoline-type photoconductive compns.)

RN 41474-55-9 CAPLUS

CN Benzothiazolium, 2-[2-[2-(dimethylamino)-4-phenyl-5-thiazolyl]ethenyl]-3-ethyl-6-nitro-, iodide (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1973:425684 CAPLUS Full-text
DOCUMENT NUMBER:	79:25684
TITLE:	Polymethine sensitizers for direct-positive emulsions
INVENTOR(S):	Riester, Oskar; Oehlschlaeger, Hans; Odenwaelder, Heinrich
PATENT ASSIGNEE(S):	Agfa-Gevaert A.-G.
SOURCE:	Ger. Offen., 28 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2142967	A1	19730308	DE 1971-2142967	19710827
BE 787442	A2	19730212	BE 1972-1004289	19720811
US 3846137	A	19741105	US 1972-282968	19720823
GB 1392127	A	19750430	GB 1972-39408	19720824
FR 2150884	A1	19730413	FR 1972-30441	19720825
CH 566572	A	19750915	CH 1972-12610	19720825
CA 995052	A1	19760817	CA 1972-150158	19720825
JP 48032528	A2	19730428	JP 1972-85464	19720828

PRIORITY APPLN. INFO.: DE 1971-2142967 A 19710827

GI For diagram(s), see printed CA Issue.

AB Previously described polymethine dyes from heterocyclic base constituents of cyanine dyes with a CN, NO2, or acyl group at a lateral CH group of the polymethine chain, 20-70 mg/kg, are particularly suitable for direct pos. emulsions because their sensitizing curve is steep and they leave little strain. The sensitizing maxs. of 51 examples vary between 515 and 655 nm. Thus, 2-(cyanomethylene)-3-ethylbenzothiazole 1.0 g and 4-(acetanilidovinyl)-1,3-dimethyl-2-pyrimidone perchlorate 1.7 g were refluxed in Ac2O 10 ml for 10 min to yield I, a typical dye with a sensitizing max. at 580 nm.

IT 42905-72-6 42905-87-3
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. sensitizer, for direct-pos. emulsions)

RN 42905-72-6 CAPLUS

CN Benzothiazolium, 2-[1-cyano-2-[2-(dimethylamino)-4-phenyl-5-thiazolyl]ethenyl]-3-ethyl-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 48221-76-7
CMF C23 H21 N4 S2



CM 2

CRN 14797-73-0
CMF Cl O4



RN 42905-87-3 CAPLUS
CN Thiazolium, 2-[1-cyano-2-[2-(dimethylamino)-4,5-dihydro-4-phenyl-5-thiazolyl]ethenyl]-4,5-dihydro-3-methyl-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 48202-94-4
CMF C18 H21 N4 S2



CM 2

CRN 14797-73-0
CMF Cl O4



102(b)

L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:104458 CAPLUS Full-text
DOCUMENT NUMBER: 78:104458
TITLE: Cyanine dye-sensitized direct-positive photographic emulsions
INVENTOR(S): Oehlschlaeger, Hans; Riester, Oskar; Dorlars, Alfons
PATENT ASSIGNEE(S): Agfa-Gevaert A.-G.
SOURCE: Ger. Offen., 25 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2132937	A1	19730118	DE 1971-2132937	19710702
BE 785075	A2	19721219	BE 1972-4119	19720619
US 3816138	A	19740611	US 1972-267165	19720628
FR 2144723	A1	19730216	FR 1972-23898	19720630
IT 960910	A	19731130	IT 1972-51242	19720630

GB 1378548	A	19741227	GB 1972-30760		19720630
CH 566025	A	19750829	CH 1972-9899		19720630
CA 1040917	A1	19781024	CA 1972-146108		19720630
PRIORITY APPLN. INFO.:			DE 1971-2132937	A	19710702

GI For diagram(s), see printed CA Issue.

AB The title emulsions contg. a cyanine dye I(R, R1 = H or RR1 = CH:CHCH:CH or CH:C(NO2)CH:CH; R2 = Me or Et; R3 = Me or Ph; R4 = SMe NMePh, or NMe2; Y = I or MeSO4) or II (X = O or S) were prepd. Thus, 45 mgI (RR1 = CH:CHCH:CH; R2 = H; R3 = Et; R4 = SMe; Y = I) was added as 1:1000 I-MeOH soln. to 1 kg direct-pos. emulsion contg. 0.4 mole Ag halide/kg (2.5 mole % I with respect to Ag). After 10 min, 10 ml 4% saponin soln. and 5% mucochloric acid were added, the emulsion was coated on a cellulose acetate support, exposed, developed, and fixed to give a pos. image of good contrast.

IT 41474-49-1
RL: TEM (Technical or engineered material use); USES (Uses)
(photographic sensitizer)

RN 41474-49-1 CAPLUS

CN Benzothiazolium, 2-[2-[2-(dimethylamino)-5-thiazolyl]ethenyl]-3-ethyl-6-nitro-, iodide (9CI) (CA INDEX NAME)



IT 41474-55-9
RL: TEM (Technical or engineered material use); USES (Uses)
(photographic sensitizer, for direct-pos. emulsions)

RN 41474-55-9 CAPLUS

CN Benzothiazolium, 2-[2-[2-(dimethylamino)-4-phenyl-5-thiazolyl]ethenyl]-3-ethyl-6-nitro-, iodide (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1972:514421 CAPLUS Full-text

DOCUMENT NUMBER: 77:114421

TITLE: Condensation of N,N-(dialkylamino)thiophenes and thiazoles with compounds containing active methylene

groups

INVENTOR(S): Scheithauer, Steffen; Hartmann, Horst; Morgenstern, Johannes

SOURCE: Ger. (East), 3 pp.
CODEN: GEXXA8

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 87576		19720205	DD 1969-144637	19691224

GI For diagram(s), see printed CA Issue.

AB The 5-morpholinothiophene-2-carboxaldehyde analogs (I, R = C(CN)2, 2,4,6-trioxohexahydro-5-pyrimidinylidene, 4-oxo-2-thioxo-5- thiazolidinylidene, 4-oxo-2-thioxo-5-imidazolidinylidene, 5,6-dimethyl-2-benzothia-zolylmethylene ethiodide, 2-quinolylmethylene ethiodide, R1 = Ph, H) were prepd. by condensing the aldehydes (I, R = O) with H2C(CN)2 or the heterocycles. 5-(2-Phenyl-5-morpholino-4- thienylmethylene)-N,N'-dimethylbarbituric acid, 5-(2-dimethylamino-4- phenyl-5-thiazolylmethylene)barbituric acid, and 3-ethyl-2-[(.beta.-(2- dimethylamino-4-phenyl-5-thiazolyl)vinyl]-benzothiazolium iodide were similarly prepd.

IT 38344-29-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 38344-29-5 CAPLUS

CN Benzothiazolium, 2-[2-[2-(dimethylamino)-4-phenyl-5-thiazolyl]ethenyl]-3-ethyl-, iodide (9CI) (CA INDEX NAME)



=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

FULL ESTIMATED COST	72.00	239.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.50	-10.50

STN INTERNATIONAL LOGOFF AT 15:06:08 ON 13 DEC 2006